Psychiatry & Neurology Doctors in Colchester, VT Accepting Medicare

2 Psychiatry & Neurology doctors found. Showing 1 - 2

Dr. Susan Wehry, M.D. Psychiatry & Neurology - Geriatric Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 792 College Pkwy, Colchester, VT 05446 Phone: 802-847-2345

Dr. Susan Leigh Deppe, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1565 Colchester Point Rd, Colchester, VT 05446 Phone: 802-658-7441    Fax: 802-658-7441

News Archive

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

Efforts to reach fiscal deal gain momentum

Some Capitol Hill lawmakers are increasingly pushing to find a way to avert a fiscal crisis. Also in the news from Congress, Republicans continue their investigation of the White House's negotiations with health care interest groups during the health law debate in 2009.

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

Study provides insights into prediction and prevention of Asian dust-related acute myocardial infarctions

When Asian dust clouds blow in to Japan's Kumamoto Prefecture, hospitals in the region handle a surge of acute myocardial infarctions (AMI) in the following 24 hours, and now a new prediction tool could help pinpoint which patients are at greatest risk.

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.

Read more Medical News

› Verified 3 days ago